1,https://www.reuters.com/article/us-health-coronavirus-canada-vaccine/health-canada-finds-astrazeneca-covid-19-vaccines-from-baltimore-plant-safe-of-high-quality-idUSKBN2CD00U,"April 26, 2021 12:32 AM UTC","Health Canada finds Astrazeneca COVID-19 vaccines from Baltimore plant safe, of high quality",Canada's health department said on Sunday the 1.5 million doses of the Astrazeneca Plc (AZN.L) COVID-19 vaccine imported from Emergent BioSolutions' (EBS.N) Baltimore facility were safe and met quality specifications.,The U.S. Food and Drug Administration (FDA) had stopped AstraZeneca from using the facility earlier this month and halted production of Johnson & Johnson's (JNJ.N) vaccine at the plant as it began investigations into an error that led to millions of doses of J&J's vaccine being ruined last month. read more,"However, Health Canada said it reviewed test results of all vaccine lots that came into the country and found them to be safe.","J&J doses produced at the Baltimore, Maryland, site have not entered the country, the regulator said, adding that vaccines from the company anticipated to be imported next week were not made at that facility.",
2,https://www.reuters.com/article/us-health-coronavirus-johnson-johnson-em/peeling-paint-shoddy-cleanups-among-issues-at-u-s-plant-making-jj-covid-19-vaccine-fda-idUSKBN2C81Z9,"April 22, 2021 3:15 AM UTC","Peeling paint, shoddy cleanups among issues at U.S. plant making J&J COVID-19 vaccine: FDA","A U.S. plant that was making Johnson & Johnson’s (JNJ.N) COVID-19 vaccine must fix a long list of problems including peeling paint, shoddy cleanups, and poorly-trained staff to resume operation, according to a highly critical report by the Food and Drug Administration.",Experts said addressing the issues raised in the scathing FDA inspection report could take months.,"Neither J&J nor the FDA has said when they expect vaccine production to resume at the Baltimore plant owned by Emergent Biosolutions Inc (EBS.N). Only one plant, in the Netherlands, is currently producing the key drug substance used in J&J's vaccine, the company said.","""It may take many months to make these changes,"" said Prashant Yadav, a global healthcare supply-chain expert at the Center for Global Development. He described some of the issues raised by the FDA as ""quite significant.""",J&J said it would ensure that all of the FDA issues are addressed promptly and comprehensively.,"The 12-page report described dirty facilities and many instances of potential contamination. In some cases, employees carrying unsealed medical waste collided with containers used to make material for vaccines, it noted, adding that containers had been spotted elsewhere with cracks.","Problems were not investigated and cleanups were superficial, it added. In one example, a worker moved between rooms where different materials were being made on 19 different days while only documenting a single required shower, the report said.","FDA inspectors said the facility was not large enough, describing crowded rooms difficult to walk through without bumping into containers of materials and small doors that forced workers to push containers on the ground rather than use machines to carry them.","""Paint flecks were observed on the floor all along the sides of these walls"" on corridors surrounding the manufacturing room and in a room were vials were filled, it said in one section, adding that there was ""brown residue"" on the wall and ""black residue"" on the floor in one plant room.","The investigation confirmed media reports that J&J shots made at the Emergent plant had been contaminated with material used to make vaccine for AstraZeneca (AZN.L). At the time, workers responded to the mix up with little more than a routine cleaning, it noted.","Millions of J&J doses were ruined, the New York Times reported. Production of AstraZeneca's vaccine was moved elsewhere.","""There is no assurance that other batches have not been subject to cross-contamination,"" the report said.",J&J has drawn scrutiny for months over its halting process to scale up production of the one-shot vaccine that is easier to handle and use than other authorized vaccines.,Its use in the United States has been paused since last week as health officials study a possible link to a very rare but serious blood clot condition.,"Emergent has been seeking regulatory authorization to make the J&J vaccine in the United States. It stopped production at the plant recently, saying the FDA had asked it to do so after an inspection.","""What's important is that the FDA caught these deficiencies"" and took steps to ensure the vaccine produced there was not used, said vaccine researcher Dr. Anna Durbin of Johns Hopkins University in Baltimore.","""Emergent has some work to do to clean up their process. They will likely need to be re-inspected by the FDA before any vaccine produced there would be accepted,"" she said.","Johnson & Johnson reiterated on Wednesday that it was working to establish a global supply chain in which 10 manufacturing sites would be involved in production of its COVID-19 vaccine, in addition the Netherlands plant.","The company has a U.S. government-brokered agreement with rival drugmaker Merck & Co (MRK.N), which is preparing to make doses of J&J’s vaccine.",FAILURE TO TRAIN PERSONNEL,The inspection report said the FDA team had reviewed security camera footage in addition to an in-person site visit to the Emergent plant.,It found failure to train personnel to avoid cross contamination of COVID-19 vaccines from Johnson & Johnson (JNJ.N) and AstraZeneca.,"Earlier this week, the U.S. House Representatives launched an investigation into whether Emergent used its relationship with a Trump administration official to get a vaccine manufacturing contract despite a record of not delivering on contracts.",Emergent said in a statement that it is working with the FDA and J&J to quickly resolve the issues outlined in the report.,"The inspection, carried out between April 12 and April 20, also noted that Emergent did not produce adequate reports showing that the vaccines it was producing met quality standards.",J&J said it was redoubling its efforts to get authorization for the facility as quickly as possible.,"J&J's oversight could help Emergent better address the FDA's concerns, none of which are especially difficult to fix, Cantor Fitzgerald analyst Brandon Folkes said in a note.",No vaccine manufactured at the Baltimore plant has been distributed for use in the United States.
3,https://www.reuters.com/article/health-coronavirus-johnsonjohnson-emerge/rpt-update-1-u-s-fda-finds-peeling-paint-debris-at-u-s-plant-making-jjs-covid-19-vaccine-idUSL4N2ME34C,"April 22, 2021 3:15 AM UTC","RPT-UPDATE 1-U.S. FDA finds peeling paint, debris at U.S. plant making J&J's COVID-19 vaccine","A U.S. plant that was making Johnson & Johnson’s (JNJ.N) COVID-19 vaccine must fix a long list of problems including peeling paint, shoddy cleanups, and poorly-trained staff to resume operation, according to a highly critical report by the Food and Drug Administration.",Experts said addressing the issues raised in the scathing FDA inspection report could take months.,"Neither J&J nor the FDA has said when they expect vaccine production to resume at the Baltimore plant owned by Emergent Biosolutions Inc (EBS.N). Only one plant, in the Netherlands, is currently producing the key drug substance used in J&J's vaccine, the company said.","""It may take many months to make these changes,"" said Prashant Yadav, a global healthcare supply-chain expert at the Center for Global Development. He described some of the issues raised by the FDA as ""quite significant.""",J&J said it would ensure that all of the FDA issues are addressed promptly and comprehensively.,"The 12-page report described dirty facilities and many instances of potential contamination. In some cases, employees carrying unsealed medical waste collided with containers used to make material for vaccines, it noted, adding that containers had been spotted elsewhere with cracks.","Problems were not investigated and cleanups were superficial, it added. In one example, a worker moved between rooms where different materials were being made on 19 different days while only documenting a single required shower, the report said.","FDA inspectors said the facility was not large enough, describing crowded rooms difficult to walk through without bumping into containers of materials and small doors that forced workers to push containers on the ground rather than use machines to carry them.","""Paint flecks were observed on the floor all along the sides of these walls"" on corridors surrounding the manufacturing room and in a room were vials were filled, it said in one section, adding that there was ""brown residue"" on the wall and ""black residue"" on the floor in one plant room.","The investigation confirmed media reports that J&J shots made at the Emergent plant had been contaminated with material used to make vaccine for AstraZeneca (AZN.L). At the time, workers responded to the mix up with little more than a routine cleaning, it noted.","Millions of J&J doses were ruined, the New York Times reported. Production of AstraZeneca's vaccine was moved elsewhere.","""There is no assurance that other batches have not been subject to cross-contamination,"" the report said.",J&J has drawn scrutiny for months over its halting process to scale up production of the one-shot vaccine that is easier to handle and use than other authorized vaccines.,Its use in the United States has been paused since last week as health officials study a possible link to a very rare but serious blood clot condition.,"Emergent has been seeking regulatory authorization to make the J&J vaccine in the United States. It stopped production at the plant recently, saying the FDA had asked it to do so after an inspection.","""What's important is that the FDA caught these deficiencies"" and took steps to ensure the vaccine produced there was not used, said vaccine researcher Dr. Anna Durbin of Johns Hopkins University in Baltimore.","""Emergent has some work to do to clean up their process. They will likely need to be re-inspected by the FDA before any vaccine produced there would be accepted,"" she said.","Johnson & Johnson reiterated on Wednesday that it was working to establish a global supply chain in which 10 manufacturing sites would be involved in production of its COVID-19 vaccine, in addition the Netherlands plant.","The company has a U.S. government-brokered agreement with rival drugmaker Merck & Co (MRK.N), which is preparing to make doses of J&J’s vaccine.",FAILURE TO TRAIN PERSONNEL,The inspection report said the FDA team had reviewed security camera footage in addition to an in-person site visit to the Emergent plant.,It found failure to train personnel to avoid cross contamination of COVID-19 vaccines from Johnson & Johnson (JNJ.N) and AstraZeneca.,"Earlier this week, the U.S. House Representatives launched an investigation into whether Emergent used its relationship with a Trump administration official to get a vaccine manufacturing contract despite a record of not delivering on contracts.",Emergent said in a statement that it is working with the FDA and J&J to quickly resolve the issues outlined in the report.,"The inspection, carried out between April 12 and April 20, also noted that Emergent did not produce adequate reports showing that the vaccines it was producing met quality standards.",J&J said it was redoubling its efforts to get authorization for the facility as quickly as possible.,"J&J's oversight could help Emergent better address the FDA's concerns, none of which are especially difficult to fix, Cantor Fitzgerald analyst Brandon Folkes said in a note.",No vaccine manufactured at the Baltimore plant has been distributed for use in the United States.
4,https://www.reuters.com/article/us-health-coronavirus-emergent-bio/jj-covid-19-vaccine-manufacturing-halted-at-u-s-plant-that-had-contamination-issue-idUSKBN2C619K,"April 19, 2021 5:04 PM UTC",J&J COVID-19 vaccine manufacturing halted at U.S. plant that had contamination issue,Production of Johnson & Johnson’s (JNJ.N) COVID-19 vaccine at a U.S. manufacturing plant was halted by the U.S. Food and Drug Administration while the agency investigates an error that led to millions of doses being ruined last month.,"Emergent BioSolutions Inc (EBS.N), the company that owns and runs the Baltimore plant that had been making the J&J vaccine, said in a regulatory filing that the FDA requested a pause on April 16 in production of new drug substance for the shot pending completion of the inspection.",Johnson & Johnson said it would work with Emergent and the FDA to address any findings at the end of the inspection.,J&J was put in charge of manufacturing at the plant in early April by the U.S. government after it disclosed the error in which ingredients from AstraZeneca’s shot (AZN.L) also being produced at the plant at that time contaminated a batch of the J&J vaccine.,"The request to pause manufacturing is the latest setback to J&J's vaccine, which has been paused for use by U.S. regulators as they review reports of rare but serious brain blood clots in people who took the one-dose shot.",The Baltimore plant had been seeking authorization from the FDA for the J&J vaccine when the error occurred. J&J has authorization to make doses in the Netherlands and finish them in the U.S. plant of Catalent Inc. (CTLT.N).,"""At this time, it is premature to speculate on any potential impact this could have on the timing of our vaccine deliveries,"" J&J said. The company has previously said it would deliver 100 million doses of its vaccine to the United States during the first half of 2021 and has so far delivered about 18 million.",J&J said in a statement it was focused on securing emergency use authorization for the Emergent plant.,Emergent said on Monday in a regulatory filing that the FDA started its review on April 12. The company said it would quarantine existing material manufactured at the Baltimore facility until the review is complete.,"""We acknowledge that there are improvements we must make to meet the high standards we have set for ourselves and to restore confidence in our quality systems and manufacturing processes,"" Emergent said in an emailed statement.","In March, J&J said it had found a problem with a batch of the drug substance for its COVID-19 vaccine being produced by Emergent.","J&J did not say how many vaccine doses the spoiled batch would have produced, but the New York Times, without citing a source, reported that about 15 million doses were ruined."
5,https://www.reuters.com/article/healthcoronavirus-emergent-bio/emergent-says-will-not-manufacture-new-covid-19-vaccine-material-at-bayview-plant-idUSL4N2MC2J3,"April 19, 2021 5:04 PM UTC",Emergent says will not manufacture new COVID-19 vaccine material at Bayview plant,Production of Johnson & Johnson’s (JNJ.N) COVID-19 vaccine at a U.S. manufacturing plant was halted by the U.S. Food and Drug Administration while the agency investigates an error that led to millions of doses being ruined last month.,"Emergent BioSolutions Inc (EBS.N), the company that owns and runs the Baltimore plant that had been making the J&J vaccine, said in a regulatory filing that the FDA requested a pause on April 16 in production of new drug substance for the shot pending completion of the inspection.",Johnson & Johnson said it would work with Emergent and the FDA to address any findings at the end of the inspection.,J&J was put in charge of manufacturing at the plant in early April by the U.S. government after it disclosed the error in which ingredients from AstraZeneca’s shot (AZN.L) also being produced at the plant at that time contaminated a batch of the J&J vaccine.,"The request to pause manufacturing is the latest setback to J&J's vaccine, which has been paused for use by U.S. regulators as they review reports of rare but serious brain blood clots in people who took the one-dose shot.",The Baltimore plant had been seeking authorization from the FDA for the J&J vaccine when the error occurred. J&J has authorization to make doses in the Netherlands and finish them in the U.S. plant of Catalent Inc. (CTLT.N).,"""At this time, it is premature to speculate on any potential impact this could have on the timing of our vaccine deliveries,"" J&J said. The company has previously said it would deliver 100 million doses of its vaccine to the United States during the first half of 2021 and has so far delivered about 18 million.",J&J said in a statement it was focused on securing emergency use authorization for the Emergent plant.,Emergent said on Monday in a regulatory filing that the FDA started its review on April 12. The company said it would quarantine existing material manufactured at the Baltimore facility until the review is complete.,"""We acknowledge that there are improvements we must make to meet the high standards we have set for ourselves and to restore confidence in our quality systems and manufacturing processes,"" Emergent said in an emailed statement.","In March, J&J said it had found a problem with a batch of the drug substance for its COVID-19 vaccine being produced by Emergent.","J&J did not say how many vaccine doses the spoiled batch would have produced, but the New York Times, without citing a source, reported that about 15 million doses were ruined."
6,https://www.reuters.com/article/us-health-coronavirus-biden-astrazeneca/u-s-working-with-astrazeneca-to-find-new-vaccine-production-sites-white-house-idUSKBN2BS1RO,2021-04-05T18:54:07Z,U.S. working with AstraZeneca to find new vaccine production sites: White House,"WASHINGTON (Reuters) - The Biden administration is working with AstraZeneca to identify other facilities to produce its coronavirus vaccine after the contractor Emergent BioSolutions mixed up ingredients for two vaccines, White House spokeswoman Jen Psaki said on Monday.","AstraZeneca, whose vaccine has not been approved in the United States, said it will work with President Joe Biden’s administration to find an alternative site to produce its vaccine."
7,https://www.reuters.com/article/us-health-coronavirus-usa-whitehouse/white-house-says-removal-of-astrazeneca-vaccine-from-u-s-plant-will-not-affect-dose-output-idUSKBN2BS1GA,2021-04-05T18:00:50Z,White House says removal of AstraZeneca vaccine from U.S. plant will not affect dose output,"(Reuters) -A U.S. government decision to end production of AstraZeneca’s COVID-19 vaccine at Emergent BioSolutions Inc’s Baltimore manufacturing facility is not an indication of concerns about its safety or effectiveness and will not impact the output of doses, a White House official said on Monday.",The U.S. Department of Health and Human Services (HHS) ordered Johnson & Johnson to take charge of production at the plant that was being used to produce both vaccines. Emergent was told to stop making AstraZeneca’s shot after the contract manufacturer made an error that ruined 15 million J&J COVID-19 vaccine doses.,"“This is not a decision that in any way has anything to do with any concerns about the AstraZeneca vaccine,” White House COVID-19 adviser Andy Slavitt told reporters during a virtual news conference.","The AstraZeneca shot, which is being used in dozens of countries, has been under increased scrutiny over reports of extremely rare but serious blood clots in the brain in some people who received the vaccine.","The U.S. manufacturing mistake occurred several weeks ago, when it was discovered that a batch of J&J vaccine had been contaminated with ingredients from AstraZeneca’s vaccine, the New York Times reported last week.",J&J on Saturday reiterated that it will deliver 100 million doses to the government by the end of May. Emergent said on Sunday would ramp down production of AstraZeneca’s COVID-19 vaccine at the Baltimore plant.,"AstraZeneca, whose vaccine has not yet been authorized for use in the United States, said it will work with President Joe Biden’s administration to find an alternative production site.","“This is a decision that HHS made with Johnson & Johnson and AstraZeneca in complete collaboration,” Slavitt said.",Slavitt also said during Monday’s briefing that nearly one-in-three Americans have had at least one COVID-19 shot and more than 55% of seniors have been fully vaccinated.,"However, average daily coronavirus infections have increased 7% over the previous seven-day period to around 64,000 daily, Dr. Rochelle Walensky, head of the U.S. Centers for Disease Control and Prevention, told reporters on Monday.","The United States has shipped out nearly 208 million COVID-19 shots and administered more than 165 million, according to federal data last updated on Sunday."
8,https://www.reuters.com/article/health-coronavirus-usa-whitehouse/white-houses-removal-of-astrazeneca-covid-19-shot-production-from-emergent-plant-wont-affect-its-dose-output-official-idUSW1N2KZ02P,"April 5, 2021 5:33 PM UTC",White House's removal of AstraZeneca COVID-19 shot production from Emergent plant won't affect its dose output - official,"A U.S. government decision to end production of AstraZeneca's (AZN.L) COVID-19 vaccine at Emergent BioSolutions Inc's (EBS.N) Baltimore manufacturing facility is not an indication of concerns about its safety or effectiveness and will not impact the output of doses, a White House official said on Monday.",The U.S. Department of Health and Human Services (HHS) ordered Johnson & Johnson (JNJ.N) to take charge of production at the plant that was being used to produce both vaccines. Emergent was told to stop making AstraZeneca's shot after the contract manufacturer made an error that ruined 15 million J&J COVID-19 vaccine doses. read more,"""This is not a decision that in any way has anything to do with any concerns about the AstraZeneca vaccine,"" White House COVID-19 adviser Andy Slavitt told reporters during a virtual news conference.","The AstraZeneca shot, which is being used in dozens of countries, has been under increased scrutiny over reports of extremely rare but serious blood clots in the brain in some people who received the vaccine.","The U.S. manufacturing mistake occurred several weeks ago, when it was discovered that a batch of J&J vaccine had been contaminated with ingredients from AstraZeneca's vaccine, the New York Times reported last week.",J&J on Saturday reiterated that it will deliver 100 million doses to the government by the end of May. Emergent said on Sunday would ramp down production of AstraZeneca’s COVID-19 vaccine at the Baltimore plant. read more,"AstraZeneca, whose vaccine has not yet been authorized for use in the United States, said it will work with President Joe Biden's administration to find an alternative production site.","""This is a decision that HHS made with Johnson & Johnson and AstraZeneca in complete collaboration,"" Slavitt said.",Slavitt also said during Monday's briefing that nearly one-in-three Americans have had at least one COVID-19 shot and more than 55% of seniors have been fully vaccinated.,"However, average daily coronavirus infections have increased 7% over the previous seven-day period to around 64,000 daily, Dr. Rochelle Walensky, head of the U.S. Centers for Disease Control and Prevention, told reporters on Monday.","The United States has shipped out nearly 208 million COVID-19 shots and administered more than 165 million, according to federal data last updated on Sunday. read more",,
9,https://www.reuters.com/article/us-health-coronavirus-astrazeneca-johnso/u-s-puts-jj-in-charge-of-plant-that-botched-covid-vaccine-removes-astrazeneca-idUSKBN2BR00Q,2021-04-05T13:14:36Z,"U.S. puts J&J in charge of plant that botched COVID vaccine, removes AstraZeneca","(Reuters) - The United States has put Johnson and Johnson in charge of a plant that ruined 15 million doses of its COVID-19 vaccine and has stopped British drugmaker AstraZeneca Plc from using the facility, a senior health official said on Saturday.","J&J said it was “assuming full responsibility” of the Emergent BioSolutions facility in Baltimore, reiterating that it will deliver 100 million doses to the government by the end of May.","In a separate statement late Sunday, Emergent said it expects to align with the U.S. government and AstraZeneca to ramp down manufacturing for AstraZeneca’s COVID-19 vaccine at its Baltimore plant.","The Department of Health and Human Services has also increased Emergent’s order by $23 million for expansion of production specific to J&J’s vaccine doses, Emergent added.","“The $23 million will be used for the purchase of biologics manufacturing equipment specific to Johnson & Johnson’s COVID-19 vaccine for the potential expansion of manufacturing of that bulk drug substance into a third suite of Emergent’s Baltimore Bayview facility,” the company said.","The Department of Health and Human Services facilitated the move, the health official said in an email, asking not to be named due to the sensitivity of the matter.","AstraZeneca, whose vaccine has not been approved in the United States, said it will work with President Joe Biden’s administration to find an alternative site to produce its vaccine.",White House officials did not immediately respond to a request for comment.,"The development, first reported by the New York Times, further hampers AstraZeneca’s efforts in the United States. The government has criticized the drugmaker for using outdated data in the results of its vaccine trial. It later revised its study.","Workers at the Emergent BioSolutions plant several weeks ago conflated ingredients for the J&J and AstraZeneca vaccines, the Times said earlier in the week. J&J said at the time the ruined batch had not advanced to the fill-and-finish stage.","The government’s move to have the facility make only the J&J single-dose vaccine is meant to avoid future mix-ups, the Times said, citing two senior federal health officials.",The top U.S. infectious disease doctor told Reuters on Thursday the country may not need AstraZeneca’s vaccine even if it wins approval.,"The United States has loan deals to send Mexico and Canada roughly 4 million doses of the AstraZeneca vaccine, made at its U.S. facility."
10,https://www.reuters.com/article/us-health-coronavirus-emergent-bio-u-s/emergent-gets-23-million-additional-order-for-vaccine-production-idUSKBN2BS05D,2021-04-05T03:05:02Z,Emergent gets $23 million additional order for vaccine production,"(Reuters) - Emergent BioSolutions Inc said late on Sunday that a key U.S. agency has increased an order, related to the manufacturing of Johnson & Johnson’s COVID-19 vaccine, by $23 million.","The amount will be used to purchase biologics equipment specific to J&J’s vaccine and support the potential manufacturing expansion at the company’s Baltimore Bayview facility, the company said in a statement.",Emergent also said that it will agree to a mutual ramp down of manufacturing of AstraZeneca Plc’s COVID-19 vaccine bulk drug substance.
11,https://www.reuters.com/article/health-coronavirus-emergent-vaccine/refile-emergent-says-it-has-disposed-of-spoilt-covid-19-vaccine-batch-idUSL4N2LU484,"April 2, 2021 12:54 AM UTC",REFILE-Emergent says it has disposed of spoilt COVID-19 vaccine batch,Johnson & Johnson's (JNJ.N) manufacturing partner Emergent Biosolutions (EBS.N) said on Thursday that it had discarded the single batch of COVID-19 drug substance that did not meet specifications.,"J&J on Wednesday said it had found a problem with a batch of the drug substance for its COVID-19 vaccine being produced at Emergent's site in Baltimore, Maryland. read more","The New York Times reported on Wednesday that about 15 million doses were ruined, without citing a source.","""Discarding a batch of bulk drug substance, while disappointing, does occasionally happen during vaccine manufacturing, which is a complex and multi-step biological process,"" Emergent said.",,
12,https://www.reuters.com/article/us-health-coronavirus-j-j-vaccine/jj-finds-problem-with-covid-vaccine-batch-nytimes-says-15-million-doses-ruined-idUSKBN2BN3GX,2021-04-01T16:27:27Z,J&J finds problem with COVID vaccine batch; NYTimes says 15 million doses ruined,"(Reuters) -Johnson & Johnson said on Wednesday it had found a problem with a batch of the drug substance for its COVID-19 vaccine being produced by Emergent Biosolutions, and said the batch did not advance to the final fill-and-finish stage.","J&J did not say how many vaccine doses the batch would have produced. The New York Times reported that about 15 million doses were ruined, without citing a source.","The Times said that workers had conflated ingredients for the J&J vaccine and a coronavirus vaccine developed by AstraZeneca Plc, which is produced at the same plant, several weeks ago.","The manufacturing misstep follows manufacturing issues at J&J, which is seen as one of the most important COVID-19 vaccines globally, because its vaccine is a single dose and requires relatively little special handling. J&J said manufacturing was on track.","J&J did not directly respond to a question about the number of doses ruined, only responding with a statement saying that the batch being produced at Emergent Biosolutions’ site in Baltimore did not meet quality standards and did not advance to the fill-and-finish stage, which is handled by another company.","J&J said the problem at the Emergent Biosolutions plant, which is not yet authorized to produce the drug substance for the vaccine, was identified and addressed with Emergent and shared with the U.S. Food and Drug Administration. J&J said it was sending more people to supervise manufacturing at the plant.",News of the setback comes at a time when the Biden administration has been trying to accelerate shipments of COVID-19 vaccines to U.S. states.,"Last month, the Biden administration said it was exploring ways to increase manufacturing of J&J’s vaccine, as the expected levels of early doses were less than it hoped at the time.",J&J said it has met its commitment to deliver more than 20 million doses of its single-shot vaccine by the end of March in the United States.,"In addition to contracting with Emergent Biosolutions to produce the vaccine drug substance, J&J tapped Catalent Inc CTLT.N to handle the final stage - called fill and finish.",Johnson & Johnson faced some manufacturing issues earlier in the year.,A European Union official in early March told Reuters that Johnson & Johnson told the bloc it was facing supply issues that might complicate plans to deliver 55 million doses of its COVID-19 vaccine in the second quarter of the year.,"Emergent, which is a manufacturing partner to both J&J and AstraZeneca, referred to J&J’s statement when contacted for comment.","Astrazeneca, whose vaccine is not yet authorized in the U.S., said: “We are aware of the reports regarding the facility and we understand Emergent is investigating the matter.”"
13,https://www.reuters.com/article/us-emergent-bio-results/vaccine-manufacturing-deals-power-emergent-biosolutions-profit-beat-idUSKBN2AI32D,2021-02-18T23:16:23Z,Vaccine manufacturing deals power Emergent BioSolutions profit beat,"(Reuters) - Emergent BioSolutions Inc beat fourth-quarter profit expectations on Thursday, benefiting from manufacturing deals to help produce COVID-19 vaccines and therapeutics.","The company has entered into more than seven manufacturing collaborations, including with AstraZeneca Plc, Johnson & Johnson, Novavax, Vaxart Inc, Humanigen Inc, since the outbreak of the pandemic.","The company said it has set up a large-scale manufacturing infrastructure, which will help it produce and supply drug substance for the vaccine candidates on time.","“We’re right online with doing that, timing-wise, as well as capability for both Johnson & Johnson and AstraZeneca Plc,” Chief Executive Robert Kramer said on a conference call with analysts.","“Specific to J&J, their short-term goal is to provide as many as 100 million doses to the U.S. government in the first half of 2021. And we’re right on schedule to support that.”",Revenue from the company’s contract development and manufacturing (CDMO) unit rose to $199.1 million in the quarter from $25.5 million a year ago.,"“Expect our CDMO business to continue to be a significant contributor to our future growth and expansion,” Kramer said.","Excluding items, Emergent earned $3.67 per share in the quarter ended Dec. 31, ahead of the analysts’ average estimate of $3.19.","Shares of the Gaithersburg, Maryland-based company were up 1.52% in extended trading."
14,https://www.reuters.com/article/emergent-bio-results/emergent-biosolutions-quarterly-profit-rises-nearly-four-times-idUSL4N2KO4A1,2021-02-18T21:11:49Z,Emergent BioSolutions quarterly profit rises nearly four times,"Feb 18 (Reuters) - Emergent BioSolutions Inc’s reported a 295% rise in quarterly profit on Thursday, helped by higher demand for its contract development and manufacturing services mainly for producing COVDID-19 vaccines and therapeutics.","Net income rose to $185.4 million, or $3.44 per share, in the fourth-quarter ended Dec. 31 from $46.9 million, or $0.90 per share, a year earlier. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shailesh Kuber)"
15,https://www.reuters.com/article/us-health-coronavirus-india-j-j/indian-drugmaker-biological-e-to-make-substance-used-in-jjs-potential-covid-19-vaccine-idUSKCN2591PI,2020-08-13T12:01:35Z,Indian drugmaker Biological E. to make substance used in J&J's potential COVID-19 vaccine,"BENGALURU (Reuters) - Indian drugmaker Biological E. Ltd will begin making a drug substance used in Johnson & Johnson’s COVID-19 vaccine candidate that is in early to mid-stage trials, the companies said on Thursday.","J&J aims to produce more than 1 billion doses of its vaccine candidate, and has struck a similar deal with U.S.-based Emergent BioSolutions Inc to boost manufacturing. Large-scale trials for the potential vaccine, Ad26.COV2-S, are set to start by October.","Twenty-eight vaccine candidates are currently in human trials, according to the World Health Organization, as the global death toll from the novel coronavirus nears 750,000.",Biological E. Ltd in an email also said it has signed a licensing agreement with Houston-based Baylor College of Medicine to develop a COVID-19 vaccine.,"Other Indian companies developing or manufacturing potential COVID-19 vaccines include the Serum Institute, Wockhardt Ltd, Cadila Healthcare Ltd and Panacea Biotec Ltd.","India on Thursday reported a record daily jump of 67,000 coronavirus infections, taking its total to nearly 2.4 million. It has the world’s third-biggest case load after the United States and Brazil."
16,https://www.reuters.com/article/us-health-coronavirus-astrazeneca-emerge/emergent-signs-174-million-deal-to-make-astrazenecas-potential-covid-19-vaccine-idUSKCN24S17K,2020-07-27T11:43:49Z,Emergent signs $174 million deal to make AstraZeneca's potential COVID-19 vaccine,(Reuters) - Emergent BioSolutions Inc said on Monday it signed a $174 million agreement with AstraZeneca to develop and manufacture the British drugmaker’s COVID-19 vaccine candidate.,AstraZeneca in June picked Emergent to help produce 300 million doses of its potential COVID-19 vaccine pledged to the United States.,"AstraZeneca has signed manufacturing deals globally to meet its target of making 2 billion doses of the vaccine, including with two Bill Gates-backed ventures and a $1.2 billion agreement with the U.S. government.","The company’s vaccine, which has been co-developed by University of Oxford, is among the first to move into mid-stage trials. There are no approved vaccines or treatments for COVID-19, the highly contagious respiratory illness caused by the novel coronavirus.",The latest contract follows an $87 million contract in June where Emergent signed an agreement to become the development partner for AstraZeneca’s COVID-19 vaccine candidate.,"Activities under the agreement will be at Emergent’s Baltimore Bayview facility, the company said, which is a designated center by the U.S. Department of Health and Human Services for rapid manufacturing of large quantities of vaccines and treatments."
17,https://www.reuters.com/article/health-coronavirus-astrazeneca-emergent/emergent-signs-174-mln-deal-to-make-astrazenecas-potential-covid-19-vaccine-idUSL3N2EY2KK,2020-07-27T10:47:51Z,Emergent signs $174 mln deal to make AstraZeneca's potential COVID-19 vaccine,July 27 (Reuters) - Emergent BioSolutions Inc said on Monday it signed a $174 million agreement with AstraZeneca to develop and manufacture the British drugmaker’s COVID-19 vaccine candidate.,AstraZeneca in June picked Emergent to help produce the 300 million doses of its potential COVID-19 vaccine pledged to the United States. (Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)
18,https://www.reuters.com/article/us-health-coronavirus-plasma-emergent-bi/emergent-to-partner-with-mount-sinai-for-potential-plasma-derived-covid-19-therapy-idUSKBN2492IR,2020-07-08T15:46:35Z,Emergent to partner with Mount Sinai for potential plasma-derived COVID-19 therapy,(Reuters) - Emergent BioSolutions Inc said on Wednesday it would jointly develop and run trials for its antibody product derived from plasma of recovered COVID-19 patients as a potential treatment with the Mount Sinai Health System.,"Under the partnership, which also includes biotech company ImmunoTek Bio Centers, Emergent will conduct a study on high-risk frontline healthcare workers and military personnel taking the experimental therapy within 72 hours after a possible exposure to the coronavirus.",The study will be aided by the $34.6 million in funding from the U.S. government granted to Emergent.,The clinical research will evaluate if treatment with Emergent’s antibody product will help protect high-risk individuals and limit the spread of COVID-19.,Emergent will also submit an experimental marketing application to the U.S. Food and Drug Administration for the product.,The company’s shares rose 5.1% to $94.03 in Wednesday morning trade.,"According to David Reich, president and chief operating officer of the Mount Sinai Hospital, a plasma-derived antibody product may be an effective option in the prevention and treatment of COVID-19 currently, in the absence of a vaccine. It may also prove helpful for patients who do not develop immunity from a vaccine.",ImmunoTek will extend its FDA license to enable plasma collection onsite at New York City’s Mount Sinai and also train staff to assist in plasma collection procedures.,"In April, Emergent was awarded $14.5 million by the U.S. Department of Health and Human Services to develop its treatment based on plasma from recovered COVID-19 patients."
19,https://www.reuters.com/article/brief-mount-sinai-health-system-emergent/brief-mount-sinai-health-system-emergent-biosolutions-and-immunotek-bio-centers-collaborate-to-develop-emergents-covid-19-hyperimmune-globulin-product-candidate-with-u-s-dod-idUSFWN2EF0KW,2020-07-08T13:46:45Z,"BRIEF-Mount Sinai Health System, Emergent Biosolutions, And Immunotek Bio Centers Collaborate To Develop Emergent's Covid-19 Hyperimmune Globulin Product Candidate With U.S. DoD",July 8 (Reuters) - Emergent BioSolutions Inc:,"* MOUNT SINAI HEALTH SYSTEM, EMERGENT BIOSOLUTIONS, AND IMMUNOTEK BIO CENTERS FORM COLLABORATION TO DEVELOP EMERGENT’S COVID-19 HYPERIMMUNE GLOBULIN (COVID-HIG) PRODUCT CANDIDATE WITH U.S. DEPARTMENT OF DEFENSE FUNDING","* EMERGENT BIOSOLUTIONS - IMMUNOTEK TO EXTEND OPERATING LICENSE, PROVIDE TRAINING TO MOUNT SINAI TO ESTABLISH ONSITE PLASMA COLLECTION",* EMERGENT BIOSOLUTIONS INC - COLLABORATION HAS FUNDING OF $34.6 MILLION FROM U.S. DEPARTMENT OF DEFENSE,* EMERGENT BIOSOLUTIONS - WILL EVALUATE COVID-HIG IN A POST-EXPOSURE PROPHYLAXIS STUDY IN INDIVIDUALS AT HIGH RISK OF EXPOSURE TO COVID-19,"* EMERGENT BIOSOLUTIONS - WILL SUPPORT IMMUNOTEK, MOUNT SINAI IN OTHER REGULATORY, COMPLIANCE EFFORTS RELATED TO PLASMA COLLECTION & SUPPLY Source text for Eikon: Further company coverage:"
20,https://www.reuters.com/article/us-health-coronavirus-emergent-bio-johns/emergent-signs-five-year-deal-backing-jj-covid-19-vaccine-idUSKBN24718P,2020-07-06T12:32:55Z,Emergent signs five-year deal backing J&J COVID-19 vaccine,"(Reuters) - Emergent BioSolutions Inc EBS.N said on Monday it signed a five-year contract to make the drug substance used in Johnson & Johnson's JNJ.N COVID-19 vaccine candidate, adding to a series of deals likely to put it at the heart of future global vaccine production.","Under the deal, starting next year Emergent will provide large-scale manufacturing services to produce the drug substance over five years, with the first two years valued at about $480 million.","The news follows a $135 million deal struck by the two companies in April, to use Emergent’s manufacturing facilities to speed up the development and production of its vaccine candidate.","J&J has partnered with the U.S. government on a $1 billion investment to produce more than 1 billion doses of its vaccine, which is set to enter human testing in the second half of this month.","The manufacturing activities will happen at Emergent’s Baltimore Bayview facility, the company said. The facility was set up by the U.S. Department of Health and Human Services (HHS) to develop and make medical countermeasures, such as vaccines and therapeutics used to fight health emergencies.","The facility, designated by the HHS as a Center for Innovation in Advanced Development and Manufacturing, has the capacity to produce tens to hundreds of millions of doses of vaccine yearly, Emergent said.","Emergent has also signed similar deals to expand the manufacturing capacity of COVID-19 vaccines under development by AstraZeneca Plc AZN.L, Novavax Inc NVAX.O and Vaxart Inc VXRT.O.","The company also received $628 million from the U.S. government, which is looking to secure manufacturing capacity for a potential COVID-19 vaccine under its “Operation Warp Speed” program."
21,https://www.reuters.com/article/brief-emergent-biosolutions-says-will-be/brief-emergent-biosolutions-says-will-begin-providing-large-scale-drug-substance-manufacturing-for-johnson-johnsons-adenovirus-based-covid-19-vaccine-in-2021-idUSFWN2ED066,2020-07-06T11:20:21Z,BRIEF-Emergent Biosolutions Says Will Begin Providing Large-Scale Drug Substance Manufacturing For Johnson & Johnson's Adenovirus-Based Covid-19 Vaccine In 2021,July 6 (Reuters) - Emergent BioSolutions Inc:,* EMERGENT BIOSOLUTIONS SIGNS FIVE-YEAR AGREEMENT FOR LARGE-SCALE DRUG SUBSTANCE MANUFACTURING FOR JOHNSON & JOHNSON’S LEAD COVID-19 VACCINE CANDIDATE,* EMERGENT BIOSOLUTIONS- WILL BEGIN PROVIDING LARGE-SCALE DRUG SUBSTANCE MANUFACTURING FOR JOHNSON & JOHNSON’S ADENOVIRUS-BASED COVID-19 VACCINE IN 2021,* EMERGENT BIOSOLUTIONS INC - WILL PROVIDE AN UPDATE TO ITS 2020 FINANCIAL OUTLOOK INCORPORATING EXPECTATIONS RELATED TO AGREEMENT,* EMERGENT - WILL PROVIDE SERVICES PRODUCE DRUG SUBSTANCE AT LARGE SCALE FOR COMMERCIAL MANUFACTURING WITH FIRST 2 YEARS VALUED AT ABOUT $480 MILLION,"* EMERGENT BIOSOLUTIONS -FOR REMAINING 3 YEARS BEGINNING IN 2023, CO WILL PROVIDE FLEXIBLE CAPACITY DEPLOYMENT MODEL TO SUPPORT ANNUAL DOSE REQUIREMENTS Source text for Eikon: Further company coverage:"
22,https://www.reuters.com/article/health-coronavirus-emergent-bio-johnsonj/emergent-to-make-drug-substance-for-jjs-covid-19-vaccine-candidate-idUSL4N2ED2GL,2020-07-06T10:51:12Z,Emergent to make drug substance for J&J's COVID-19 vaccine candidate,"July 6 (Reuters) - Emergent BioSolutions Inc said on Monday it has signed a five-year pact to make the drug substance used in Johnson & Johnson’s COVID-19 vaccine candidate, in a deal valued at about $480 million for the first two years.",Johnson & Johnson had struck a deal with Emergent in April to use its manufacturing facilities and make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Ramakrishnan M.)
23,https://www.reuters.com/article/brief-emergent-biosolutions-to-invest-75/brief-emergent-biosolutions-to-invest-75-mln-in-canton-site-and-expand-viral-vector-and-gene-therapy-capability-idUSFWN2DV0C1,2020-06-18T11:23:41Z,BRIEF-Emergent Biosolutions To Invest $75 Mln In Canton Site And Expand Viral Vector And Gene Therapy Capability,June 18 (Reuters) - Emergent BioSolutions Inc:,* EMERGENT BIOSOLUTIONS TO INVEST $75 MILLION IN CANTON SITE AND EXPAND VIRAL VECTOR AND GENE THERAPY CAPABILITY,* EMERGENT BIOSOLUTIONS INC - ADVANCED THERAPY CDMO DRUG SUBSTANCE MANUFACTURING SERVICES EXPECTED TO BE AVAILABLE BEGINNING IN 2023 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
24,https://www.reuters.com/article/brief-emergent-biosolutions-to-become-us/brief-emergent-biosolutions-to-become-u-s-manufacturing-partner-for-astrazenecas-covid-19-vaccine-candidate-idUSFWN2DO0D5,2020-06-11T13:18:23Z,BRIEF-Emergent Biosolutions To Become U.S. Manufacturing Partner For Astrazeneca's Covid-19 Vaccine Candidate,June 11 (Reuters) - Emergent BioSolutions Inc:,* EMERGENT BIOSOLUTIONS SIGNS AGREEMENT TO BE U.S. MANUFACTURING PARTNER FOR ASTRAZENECA’S COVID-19 VACCINE CANDIDATE,* EMERGENT BIOSOLUTIONS - AGREEMENT VALUED AT APPROXIMATELY $87 MILLION,"* EMERGENT BIOSOLUTIONS - TO PROVIDE DEVELOPMENT, MANUFACTURING SERVICES & CAPACITY TO INNOVATORS OF LEADING COVID-19 VACCINE CANDIDATES SELECTED BY U.S. GOVERNMENT","* EMERGENT BIOSOLUTIONS INC - UNDER AGREEMENT, CO WILL RESERVE CERTAIN LARGE-SCALE MANUFACTURING CAPACITY THROUGH 2020 Source text for Eikon: Further company coverage:"
25,https://www.reuters.com/article/health-coronavirus-astrazeneca-emergent/emergent-biosolutions-signs-87-mln-deal-to-make-astrazenecas-covid-19-vaccine-in-u-s-idUSL4N2DO2TC,2020-06-11T13:03:58Z,Emergent BioSolutions signs $87 mln deal to make AstraZeneca's COVID-19 vaccine in U.S.,"June 11 (Reuters) - Emergent BioSolutions Inc said on Thursday it signed a $87 million deal to make AstraZeneca Plc’s experimental COVID-19 vaccine in the United States, as the British drugmaker looks to ramp up its efforts to bring a vaccine to the market.","Under the agreement, Emergent will help with services involving development and analytical testing and will reserve some of its large-scale manufacturing capacity through 2020 for the vaccine. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Amy Caren Daniel)"
26,https://www.reuters.com/article/brief-emergent-biosolutions-statement-on/brief-emergent-biosolutions-statement-on-u-s-district-court-decision-idUSFWN2DI0L4,2020-06-05T23:43:15Z,BRIEF-Emergent Biosolutions Statement On U.S. District Court Decision,June 5 (Reuters) - Emergent Biosolutions Inc:,* EMERGENT BIOSOLUTIONS STATEMENT ON U.S. DISTRICT COURT DECISION,* COURT ENTERED A DECISION IN PATENT LITIGATION REGARDING NARCAN NASAL SPRAY 4MG/SPRAY PRODUCT,* EMERGENT BIOSOLUTIONS - EMERGENT INTENDS TO APPEAL DECISION TO COURT OF APPEALS FOR FEDERAL CIRCUIT,"* COURT RULED IN FAVOR OF DEFENDANTS, TEVA PHARMACEUTICALS INDUSTRIES LTD Source text for Eikon: Further company coverage:"
27,https://www.reuters.com/article/us-health-coronavirus-usa-vaccine/u-s-awards-new-628-million-contract-to-boost-output-of-potential-covid-19-vaccine-idUSKBN2382DO,2020-06-01T14:20:18Z,U.S. awards new $628 million contract to boost output of potential COVID-19 vaccine,(Reuters) - The U.S. government on Monday entered into a $628 million contract with drugmaker Emergent BioSolutions EBS.N to boost manufacturing capacity for a potential COVID-19 vaccine.,"As drugmakers race to develop vaccines, tests and therapies for the disease, the United States is looking to secure manufacturing capacity under its “Operation Warp Speed” program announced in May to accelerate vaccine development.","“Securing more manufacturing capacity here in America for candidates that make it to the final stages of Operation Warp Speed will help get a vaccine to American patients without a day wasted,” Department of Health and Human Services (HHS) Secretary Alex Azar said in a statement.","The HHS task order with Emergent falls under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), a U.S. federal agency that funds disease-fighting technology.","Under the contract, Emergent will commit its manufacturing facilities, valued at $542.7 million, to produce COVID-19 vaccine candidates through 2021.","The BARDA award secures capacity for drug manufacturing at the company’s Baltimore Bayview facility, established in 2012 with HHS, and designed for rapid manufacturing of large quantities of vaccines and treatments during public health emergencies, the company said in a statement.",The task order also includes an investment of $85.5 million to expand Emergent’s viral and non-viral drug manufacturing capacity.,"So far, BARDA has invested more than $2 billion in COVID-19 vaccines and funded over 30 projects, including for diagnostics and treatments.","The agency has awarded grants to Moderna Inc MRNA.O, the first in the United States to begin human trials of a coronavirus vaccine, Sanofi SASY.PA, Johnson & Johnson JNJ.N and British drugmaker AstraZeneca Plc AZN.L.","Emergent has been working with Johnson & Johnson, Novavax Inc NVAX.O and Vaxart Inc VXRT.O to develop and manufacture their COVID-19 vaccine candidates."
28,https://www.reuters.com/article/health-coronavirus-usa-vaccine/u-s-awards-new-628-mln-contract-to-boost-output-of-potential-covid-19-vaccine-idUSL4N2DE2TC,2020-06-01T11:50:18Z,U.S. awards new $628 mln contract to boost output of potential COVID-19 vaccine,June 1 (Reuters) - The U.S. government on Monday entered into a $628 million contract with drugmaker Emergent BioSolutions to boost manufacturing capacity for a potential COVID-19 vaccine.,"As drugmakers race to develop vaccines, tests and therapies for COVID-19, the United States is looking to secure manufacturing capacity under its “Operation Warp Speed” program announced in May to accelerate vaccine development.","“Securing more manufacturing capacity here in America for candidates that make it to the final stages of Operation Warp Speed will help get a vaccine to American patients without a day wasted,” Department of Health and Human Services (HHS) Secretary Alex Azar said in a statement.","The HHS task order with Emergent falls under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA), a U.S. federal agency that funds disease-fighting technology.","So far, BARDA has invested more than $2 billion in vaccines and funded over 30 projects, including for diagnostics and treatments.","The agency has awarded grants to Moderna Inc, the first in the United States to begin human trials of a coronavirus vaccine, Sanofi, Johnson & Johnson and British drugmaker AstraZeneca Plc.","Emergent has been working on development and manufacturing with Johnson & Johnson, Novavax Inc and Vaxart Inc on their COVID-19 vaccine candidates. (Reporting by Vishwadha Chander in Bengaluru; Editing by Saumyadeb Chakrabarty)"
29,https://www.reuters.com/article/brief-hhs-emergent-to-commit-manufacturi/brief-hhs-emergent-to-commit-manufacturing-capacity-for-production-of-covid-19-vaccine-candidates-idUSFWN2DE0GX,2020-06-01T11:30:29Z,BRIEF-HHS - Emergent To Commit Manufacturing Capacity For Production Of Covid-19 Vaccine Candidates,June 1 (Reuters) - Emergent BioSolutions Inc:,* HHS ADDS $628 MILLION TO CONTRACT WITH EMERGENT BIOSOLUTIONS TO SECURE CDMO MANUFACTURING CAPACITY FOR OPERATION WARP SPEED,"* HHS - ANNOUNCED TASK ORDER WITH EMERGENT BIOSOLUTIONS TO ADVANCE MANUFACTURING CAPABILITIES, CAPACITY FOR POTENTIAL COVID-19 VACCINE, THERAPEUTICS",* HHS - EMERGENT TO COMMIT CDMO DRUG SUBSTANCE & DRUG PRODUCT MANUFACTURING CAPACITY OF ABOUT $542.75 MILLION FOR PRODUCTION OF COVID-19 VACCINE CANDIDATESSource text for Eikon: Further company coverage:
30,https://www.reuters.com/article/brief-emergent-biosolutions-joins-us-gov/brief-emergent-biosolutions-joins-u-s-govts-warp-speed-program-for-covid-19-idUSFWN2DE06J,2020-06-01T10:34:32Z,BRIEF-Emergent Biosolutions Joins U.S. Govt's Warp Speed Program For Covid-19,June 1 (Reuters) - Emergent BioSolutions Inc:,* EMERGENT BIOSOLUTIONS JOINS U.S. GOVERNMENT’S WARP SPEED PROGRAM IN LANDMARK PUBLIC-PRIVATE CDMO PARTNERSHIP FOR COVID-19 VACCINE DEVELOPMENT AND MANUFACTURING,"* EMERGENT BIOSOLUTIONS - WILL DEPLOY ITS MOLECULE-TO-MARKET CDMO OFFERING VALUED AT ABOUT $542.7 MILLION, FOR PRODUCTION OF COVID-19 VACCINE CANDIDATES Source text for Eikon: Further company coverage:"
31,https://www.reuters.com/article/brief-emergent-biosolutions-through-unit/brief-emergent-biosolutions-through-unit-received-contract-modification-from-office-of-assistant-secretary-for-preparedness-and-response-idUSFWN2DA0VU,2020-05-28T22:22:51Z,BRIEF-Emergent Biosolutions Through Unit Received Contract Modification From Office Of Assistant Secretary For Preparedness And Response,May 28 (Reuters) - Emergent BioSolutions Inc:,* EMERGENT BIOSOLUTIONS - THROUGH UNIT RECEIVED CONTRACT MODIFICATION FROM OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE,* EMERGENT BIOSOLUTIONS - CONTRACT MODIFICATION FROM ASPR EXERCISING FIRST OF NINE ANNUAL CONTRACT OPTIONS FOR CO TO SUPPLY ACAM2000 INTO U.S. SNS,* EMERGENT BIOSOLUTIONS - FIRST OPTION EXERCISE IS VALUED AT ABOUT $176.2 MILLION,"* EMERGENT BIOSOLUTIONS - PERIOD OF PERFORMANCE UNDER FIRST OPTION EXERCISE REQUIRES EMERGENT TO DELIVER DOSES OF ACAM2000 INTO SNS BY DEC 31, 2020 Source text: (bit.ly/2ZKD3r1) Further company coverage:"
32,https://www.reuters.com/article/us-health-coronavirus-johnson-johnson/jj-strikes-deal-with-emergent-biosolutions-on-coronavirus-vaccine-manufacturing-idUSKCN2253TQ,2020-04-23T23:48:34Z,J&J strikes deal with Emergent BioSolutions on coronavirus vaccine manufacturing,(Reuters) - Johnson & Johnson said on Thursday it had struck a deal with Emergent BioSolutions Inc to use its manufacturing facilities to help in an effort to make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.,"The U.S. healthcare conglomerate said the deal was the first in a series of prospective global partnerships to accelerate manufacturing of its experimental COVID-19 vaccine candidate, even before it has a signal that it works.","J&J plans to start human testing by September, with an eye on having it ready under an emergency use authorization in early 2021, far quicker than the typical 18-month period that it takes for vaccines to be tested, approved and then manufactured.","Under the deal, valued at about $135 million, Emergent said it would provide drug substance manufacturing services and was reserving large-scale manufacturing capacity.","J&J and the U.S. government are investing $1 billion to create enough manufacturing capacity for the experimental vaccine candidate to stop the virus that has killed nearly 185,000 people around the globe."
33,https://www.reuters.com/article/brief-emergent-biosolutions-signs-agreem/brief-emergent-biosolutions-signs-agreement-to-be-u-s-manufacturing-partner-for-jjs-lead-vaccine-candidate-for-covid-19-idUSFWN2CB1GB,2020-04-23T23:03:43Z,BRIEF-Emergent Biosolutions Signs Agreement To Be U.S. Manufacturing Partner For J&J's Lead Vaccine Candidate For COVID-19,April 23 (Reuters) - Emergent Biosolutions Inc:,* EMERGENT BIOSOLUTIONS SIGNS AGREEMENT TO BE U.S. MANUFACTURING PARTNER FOR JOHNSON & JOHNSON’S LEAD VACCINE CANDIDATE FOR COVID-19,"* EMERGENT BIOSOLUTIONS - UNDER AGREEMENT, WILL PROVIDE DRUG SUBSTANCE MANUFACTURING SERVICES WITH ITS MOLECULE-TO-MARKET CDMO OFFERING Source text for Eikon: Further company coverage:"
34,https://www.reuters.com/article/brief-jj-announces-collaboration-to-expa/brief-jj-announces-collaboration-to-expand-manufacturing-capabilities-for-its-covid-19-vaccine-candidate-idUSFWN2CB1GA,2020-04-23T23:03:14Z,BRIEF-J&J Announces Collaboration To Expand Manufacturing Capabilities For Its COVID-19 Vaccine Candidate,April 23 (Reuters) - Johnson & Johnson:,* JOHNSON & JOHNSON ANNOUNCES COLLABORATION TO EXPAND MANUFACTURING CAPABILITIES FOR ITS COVID-19 VACCINE CANDIDATE IN SUPPORT OF THE COMPANY’S GOAL TO SUPPLY MORE THAN ONE BILLION VACCINE DOSES GLOBALLY,* J&J - COMPANY SIGNS AGREEMENT WITH EMERGENT BIOSOLUTIONS IN U.S. AS PART OF ITS INVESTMENT,"* J&J - UNDER TERMS, JOHNSON & JOHNSON IS INVESTING TO EXPAND DRUG SUBSTANCE CAPACITY RELATED TO VACCINE CANDIDATE","* J&J - UNDER TERMS EMERGENT WILL PROVIDE DRUG SUBSTANCE MANUFACTURING SERVICES WITH ITS MOLECULE-TO-MARKET CDMO OFFERING, BEGINNING IN 2020",* J&J - EMERGENT WILL RESERVE OPERATIONS CAPACITY TO POTENTIALLY SUPPORT COMMERCIAL MANUFACTURING OF J&J’S COVID-19 VACCINE CANDIDATE BEGINNING IN 2021,"* J&J - COMPANY HAS ALREADY BEGUN PREPARATIONS FOR CLINICAL VACCINE PRODUCTION AT ITS FACILITY IN LEIDEN, NETHERLANDS",* J&J - AIM OF INITIATING PHASE 1 HUMAN CLINICAL STUDIES OF ITS VACCINE CANDIDATE IN SEPTEMBER 2020,* J&J - WILL BEGIN PRODUCTION AT RISK AND IS COMMITTED TO BRINGING AN AFFORDABLE VACCINE TO PUBLIC ON A NOT-FOR-PROFIT BASIS FOR EMERGENCY PANDEMIC USE,"* J&J - ALSO AIMING TO RAPIDLY SCALE UP VACCINE MANUFACTURING CAPABILITIES GLOBALLY, INCLUDING INCREASING CAPACITY IN COUNTRIES OUTSIDE U.S. Source text for Eikon: Further company coverage:"
35,https://www.reuters.com/article/brief-emergent-biosolutions-inc-has-rece/brief-emergent-biosolutions-inc-has-received-14-5-million-from-barda-in-support-of-its-covid-hig-program-idUSFWN2BQ1E0,2020-04-02T20:59:56Z,BRIEF-Emergent Biosolutions Inc - Has Received $14.5 Million From Barda In Support Of Its Covid-Hig Program,Emergent BioSolutions Inc:,* EMERGENT BIOSOLUTIONS PARTNERS WITH U.S. GOVERNMENT FOR COMPREHENSIVE RESPONSE TO EXPEDITE DEVELOPMENT OF PLASMA-DERIVED THERAPY FOR COVID-19,* EMERGENT BIOSOLUTIONS INC - HAS RECEIVED $14.5 MILLION FROM BARDA IN SUPPORT OF ITS COVID-HIG PROGRAM Source text for Eikon: Further company coverage:
36,https://www.reuters.com/article/brief-emergent-biosolutions-signs-agreem/brief-emergent-biosolutions-signs-agreement-with-novavax-to-manufacture-nanoflu-idUSFWN2BO1N8,2020-03-31T21:06:23Z,BRIEF-Emergent BioSolutions Signs Agreement With Novavax To Manufacture Nanoflu,March 31 (Reuters) - Emergent BioSolutions Inc:,* EMERGENT BIOSOLUTIONS SIGNS AGREEMENT WITH NOVAVAX TO MANUFACTURE NANOFLU™,* EMERGENT BIOSOLUTIONS - WILL PROVIDE MOLECULE-TO-MARKET CONTRACT DEVELOPMENT AND MANUFACTURING SERVICES TO PRODUCE NOVAVAX’S NANOFLU Source text for Eikon: Further company coverage:
37,https://www.reuters.com/article/brief-vaxart-entered-agreement-with-emer/brief-vaxart-entered-agreement-with-emergent-biosolutions-for-development-of-oral-coronavirus-vaccine-candidate-idUSFWN2BB0LM,2020-03-18T10:39:57Z,BRIEF-Vaxart - Entered Agreement With Emergent Biosolutions For Development Of Oral Coronavirus Vaccine Candidate,March 18 (Reuters) - Vaxart Inc:,* VAXART ANNOUNCES IT ENTERED INTO AN AGREEMENT WITH EMERGENT BIOSOLUTIONS FOR THE DEVELOPMENT AND MANUFACTURING OF ORAL CORONAVIRUS (COVID-19) VACCINE CANDIDATE Source text for Eikon: Further company coverage:
38,https://www.reuters.com/article/brief-emergent-biosolutions-initiates-de/brief-emergent-biosolutions-initiates-development-of-plasma-derived-product-candidates-for-treatment-and-prevention-of-coronavirus-idUSFWN2B40RK,2020-03-11T21:17:01Z,BRIEF-Emergent BioSolutions Initiates Development Of Plasma-Derived Product Candidates For Treatment And Prevention Of Coronavirus,March 11 (Reuters) - Emergent BioSolutions Inc:,* EMERGENT BIOSOLUTIONS INITIATES DEVELOPMENT OF PLASMA-DERIVED PRODUCT CANDIDATES FOR THE TREATMENT AND PREVENTION OF CORONAVIRUS DISEASE,* EMERGENT BIOSOLUTIONS INC - EMERGENT HAS INITIATED PLASMA COLLECTION EFFORTS FOR BOTH HUMAN AND EQUINE PLATFORMS Source text for Eikon: Further company coverage:
39,https://www.reuters.com/article/brief-emergent-announces-fda-approval-of/brief-emergent-announces-fda-approval-of-change-in-storage-conditions-and-transfer-of-manufacturing-for-its-cholera-vaccine-idUSASB01P8E,2019-06-04T20:27:46Z,BRIEF-Emergent Announces FDA Approval Of Change In Storage Conditions And Transfer Of Manufacturing For Its Cholera Vaccine,June 4 (Reuters) - Emergent BioSolutions Inc:,* EMERGENT BIOSOLUTIONS ANNOUNCES FDA APPROVAL OF CHANGE IN STORAGE CONDITIONS AND TRANSFER OF MANUFACTURING FOR ITS CHOLERA VACCINE,"* EMERGENT BIOSOLUTIONS - ANNOUNCED APPROVAL BY FDA OF PRIOR APPROVAL SUPPLEMENT SUBMITTED BY CO FOR ITS ORAL CHOLERA VACCINE, VAXCHORA",* EMERGENT BIOSOLUTIONS - VAXCHORA PRIOR APPROVAL SUPPLEMENT SUPPORTS CHANGE IN STORAGE CONDITIONS OF THE VACCINE FROM FROZEN TO REFRIGERATED AT 2-8°C,* EMERGENT BIOSOLUTIONS - VAXCHORA PRIOR APPROVAL SUPPLEMENT SUPPORTS TRANSFER OF THE BULK DRUG SUBSTANCE MANUFACTURING TO MANUFACTURING FACILITY IN BERN Source text for Eikon: Further company coverage:
40,https://www.reuters.com/article/us-emergent-bio-zika/emergent-valneva-zika-vaccine-clears-early-trial-idUSKCN1NO2KT,2018-11-19T22:08:50Z,Emergent-Valneva Zika vaccine clears early trial,"(Reuters) - A vaccine to prevent infections caused by the deadly mosquito-borne Zika virus induced immune response and was found to be safe in an early stage trial, Emergent BioSolutions Inc and partner Valneva SE said on Monday.","The vaccine, VLA1601, which was tested in two doses in 67 adult patients, induced the body to produce neutralizing antibodies against the virus, the companies said.","First discovered in 1947, the Zika virus reached epidemic proportions in Brazil in 2015, when thousands of babies were born with birth defects.","However, bringing a vaccine to market has proved difficult, with drug companies including Japan’s Takeda Pharmaceutical and Inovio Pharmaceuticals Inc in the race.",Emergent announced an exclusive worldwide license deal for Valneva’s Zika vaccine technology in July last year.,"Monday’s release contained analyses up to day 56 after the first vaccination, with final analysis - at day 208 - expected in the first quarter 2019, the companies said."
41,https://www.reuters.com/article/us-adapt-pharma-m-a-emergent-bio/emergent-biosolutions-to-buy-narcan-maker-adapt-pharma-idUSKCN1LD2IO,2018-08-28T22:31:56Z,Emergent BioSolutions to buy Narcan maker Adapt Pharma,"(Reuters) - Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA approved needle-free emergency opioid overdose treatment.","Addiction to opioids - mainly prescription painkillers, heroin and fentanyl - has emerged as a serious public health crisis in the United States, especially in rural areas.","According to the U.S. Centers For Disease Control And Prevention, the epidemic here over 70,000 lives last year.",President Donald Trump in March recommended death penalty for drug dealers after declaring the addiction crisis a public health emergency in October.,"Trump also introduced an Adapt Pharma executive, Mike Kelly, during an event in New Hampshire and said he wanted to give first responders access to life-saving drugs that can reverse overdoses.","Emergent’s shares were up marginally in after-hours trading on Tuesday, while those of Opiant Pharmaceuticals, Adapt’s commercial partner, jumped nearly 42 percent.",Emergent said it had “no plans to change” Narcan’s pricing and would maintain the 40 percent discount available to state and local governments and non-profit organizations.,"“Adapt has put together a strong, durable supply chain of partners to support the manufacture of the product. We do not intend to disrupt that,” an Emergent executive said on a conference call with analysts.","Narcan, often carried by police officers and medical teams, contains the chemical naloxone hydrochloride and was approved as a nasal spray in 2015. The U.S. Surgeon General released a public health advisory earlier this year urging more Americans to carry naloxone.","Tuesday’s deal comprises an upfront cash-and-stock payment of $635 million and up to $100 million in cash linked to sales-based milestones through 2022, Emergent said.","The company will also gain access to Adapt’s pipeline of treatments to address opioid overdose, as well as about 50 employees in the United States, Canada and Ireland.",The deal fits in with Emergent’s strategy of focusing on treatments for public health threats and the company is currently developing a vaccine for bat-borne Nipah virus.,"Acquisitions will remain a priority in the growth approach, the company said.",Emergent is looking to achieve or exceed its $1 billion in revenue goal in 2020 and as part of the plan recently acquired specialty vaccines company PaxVax.
42,https://www.reuters.com/article/adapt-pharma-ma-emergent-bio/emergent-biosolutions-to-buy-adapt-pharma-for-up-to-735-mln-idUSL3N1VJ5RJ,2018-08-28T20:58:51Z,Emergent BioSolutions to buy Adapt Pharma for up to $735 mln,"Aug 28 (Reuters) - Emergent BioSolutions Inc said on Tuesday it would buy privately held Adapt Pharma for up to $735 million to acquire its drug Narcan, the only needle-free emergency treatment approved to treat opioid overdose.","The deal comprises an upfront cash-and-stock payment of $635 million and up to $100 million in cash dependent on sales-based milestones through 2022, Emergent said.","Opioid overdoses killed over 70,000 people last year, according to here the U.S. Centers For Disease Control And Prevention."
43,https://www.reuters.com/article/brief-emergent-biosolutions-reports-q1-a/brief-emergent-biosolutions-reports-q1-adjusted-loss-per-share-0-03-idUSASC09ZRZ,2018-05-03T20:54:53Z,BRIEF-Emergent BioSolutions Reports Q1 Adjusted Loss Per Share $0.03,May 3 (Reuters) - Emergent BioSolutions Inc:,* EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS,* Q1 REVENUE $117.8 MILLION VERSUS I/B/E/S VIEW $140.4 MILLION,* Q1 EARNINGS PER SHARE VIEW $0.22 -- THOMSON REUTERS I/B/E/S,* REAFFIRMS FULL YEAR 2018 FINANCIAL FORECAST AND OPERATIONAL GOALS,"* FY2018 EARNINGS PER SHARE VIEW $2.38, REVENUE VIEW $731.4 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:"
